Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Systemic Lupus Erythematosus

Low-Density Granulocytes Activate T Cells in SLE

Lara C. Pullen, PhD  |  June 17, 2019

Recent research indicates that low-density neutrophils, such as low-density granulocytes, exert proinflammatory effects on the T cells of SLE patients. In the study, researchers confirmed SLE patients had a higher prevalence of low-density granulocytes than healthy controls and that these cells appeared to promote a Th1 response…

Insight into Clinical Trials for Lupus

Thomas R. Collins  |  June 12, 2019

Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…

The Little-Known (But Not Uncommon) SSc-Lupus Overlap Syndrome

Susan Bernstein  |  May 18, 2019

What happens when systemic sclerosis (SSc) overlaps with other systemic autoimmune rheumatic diseases? Patients with either diffuse cutaneous or limited cutaneous SSc sometimes develop systemic lupus erythematosus (SLE) as well. A new, large cohort study published in the Journal of Rheumatology reveals details on the epidemiology, clinical signs and survival data of SSc-SLE overlap syndrome.1…

Update on Accelerating Medicines Partnership

From the College  |  May 17, 2019

The Accelerating Medicines Partnership (AMP) was launched in 2014 as a public-private partnership to spur development of new therapeutic options for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Five years in, this unprecedented public-private effort is achieving its major milestones and yielding tools to accelerate potential new drug discoveries. The Rheumatology Research Foundation is…

New Study Examines Cerebrovascular Events in Lupus Patients

Linda Childers  |  May 17, 2019

Stroke and transient ischemia are the most common cerebrovascular events in lupus patients, and a new study has found most of these occurrences can be attributed to lupus itself rather than other causes. The study, published in the October 2018 issue of Arthritis Care & Research, looked at the frequency, association and outcomes of cerebrovascular…

Characterization of Autoreactive B Cells in Patients with SLE & RA

Lara C. Pullen, PhD  |  May 6, 2019

Antibody-secreting cells are important for the pathophysiology of SLE and RA, but researchers have been unable to determine how these cells are activated. A new technique is able to distinguish between naïve autoreactive B cells and established antibody secreting cells…

Anti-Mitochondrial Antibodies & Systemic Lupus Erythematosus

Lara C. Pullen, PhD  |  April 29, 2019

Although antimitochondrial antibodies are present in SLE patients, researchers have has difficulty investigating the phenomenon due to barriers in isolating pure mitochondria. The study describes a technique that allows for such an investigation and provides insight into how the adaptive immune system recognizes mitochondrial organelles…

The ACR Supports Its Members Via Collaboration

Paula Marchetta, MD, MBA  |  April 15, 2019

We all know words can be powerful. They often resonate with several levels of meaning, enriching our understanding and broadening our perspective. Take the word promise, for example. It implies responsibility, as in, “We promise to do it.” It is also imbued with hope, as in “This idea has great promise.” At the ACR we…

To Bridge Health Disparities, Diagnose Lupus Early & Improve Access

Susan Bernstein  |  March 19, 2019

CHICAGO—At the 2018 ACR/ARHP Annual Meeting, rheumatologist project volunteers for the ACR’s Collaborative Initiatives talked about their efforts to educate primary-care providers, patients and families in their communities about systemic lupus erythematosus (SLE). Their goal is to facilitate timely diagnosis and treatment of lupus, especially in underserved communities. Health Disparities Health disparities, or differences in health…

Treating Lupus: Strategies, Treat to Target & Biologics

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—David A. Isenberg, MD, academic director of rheumatology, University College London, presented the ACR Systemic Lupus Erythematosus (SLE) State-of-the-Art Symposium at the 2018 ACR/ARHP Annual Meeting. Dr. Isenberg began by noting lupus is now widely covered in the news, but singer Selena Gomez has probably done the most to increase awareness of the disease; her…

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences